Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novelos files for orphan drug status on cancer treatment
In the US an orphan drug designation may be granted to drugs that treat rare life-threatening diseases that affect less than 200,000 US persons. Such designation provides a
In the US an orphan drug designation may be granted to drugs that treat rare life-threatening diseases that affect less than 200,000 US persons. Such designation provides a
Glaucoma is characterized by increased fluid pressure within the eye, or intraocular pressure, which often causes the degeneration of the optic nerve and blindness. Glaucoma is the second
Not only did the new once daily formulation of Sanctura improve all the symptoms and signs of overactive bladder, it was also was very well tolerated among the
Barr’s application to market an abbreviated form of the drug has already been accepted for filling by the FDA, triggering the response by J&J. The suit has been
The decision by the FDA to approve new prescribing information for Angiomax (bivalirudin) is effective immediately. The label will now include patients undergoing percutaneous coronary intervention (PCI) in
The phase I trial conducted in early 2005 was designed to evaluate AL-108’s safety, tolerability and pharmacokinetics in healthy subjects. The study was double-blind by design and participants
The phase I clinical trial of RiVax represents the first ricin toxin vaccine ever to be clinically tested in humans. In the dose-escalating, open-label trial, three cohorts of
The multi-center study will be conducted in more than 50 US sites recruiting around 400 patients. One-half of the postherpetic neuralgia (PHN) patients will be assigned to receive
Adjuvant chemotherapy is the standard treatment approach for Dukes’ C colon cancer (cancer that has spread to the lymph nodes), where chemotherapy is given after the tumor has
A pooled analysis of three studies involving over 680 adults with type 2 diabetes showed that participants who added Exubera to their treatment regimen maintained glycemic control over